2022

1. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

   Journal of Neurodevelopmental Disorders, Vol. 14, Núm. 1